Clinical Trial

Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 28, 2024 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Exogenous injection of recombinant human thyroid stimulating hormone (rhTSH) can elevate TSH in the short term (2 days) to meet the requirements of diagnostic 131I SPECT/CT whole-body scans. Antiangiogenic tyrosine kinase inhibitors (TKI) couuld alter the uptake of radioactive 131I in locally advanced or metastatic differentiated thyroid cancer. rhTSH can help to perform the diagnostic 131I SPECT/CT whole-body scans before and after the TKI usage. rhTSH can reduce the risk of tumor progression caused by thyroid hormone withdrawal period and the side effects of hypothyroidism also caused by thyroid hormone withdrawal, and clarify the 131I uptake change after TKI treatment.
Trial Details
NCT Number NCT06431620
Lead Sponsor Nanjing First Hospital, Nanjing Medical University
Conditions Recombinant Human Thyroid Stimulating Hormone
Enrollment 15 participants
Start Date 2024-06-30
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-05-28